# A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

> **NCT07465029** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 1300 (estimated)

## Conditions studied

- Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

## Interventions

- **DRUG:** Erythropoiesis-stimulating agents (ESAs)
- **BIOLOGICAL:** Luspatercept
- **DRUG:** Lenalidomide
- **DRUG:** Hypomethylating agents (HMAs)
- **BIOLOGICAL:** Reb blood cell transfusion

## Key facts

- **NCT ID:** NCT07465029
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 1300 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465029, "A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07465029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*